alexa Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Clinical Sciences

Clinical Sciences

Cardiovascular Pharmacology: Open Access

Author(s): Pfisterer M, BrunnerLa Rocca HP, Buser PT, Rickenbacher P, Hunziker P, , Pfisterer M, BrunnerLa Rocca HP, Buser PT, Rickenbacher P, Hunziker P,

Abstract Share this page

Abstract OBJECTIVES: We sought to define the incidence of late clinical events and late stent thrombosis in patients treated with drug-eluting (DES) versus bare-metal stents (BMS) after the discontinuation of clopidogrel as well as their timing and outcome. BACKGROUND: There is growing concern that delayed endothelialization after DES implantation may lead to late stent thrombosis and related myocardial infarction (MI) or death. However, event rates and outcomes after clopidogrel discontinuation versus BMS are unknown. METHODS: A consecutive series of 746 nonselected patients with 1,133 stented lesions surviving 6 months without major events were followed for 1 year after the discontinuation of clopidogrel. Patients were assigned randomly 2:1 to DES versus BMS in BASKET (Basel Stent Kosten Effektivitäts Trial). The primary focus of this observation was cardiac death/MI. RESULTS: Rates of 18-month cardiac death/MI were not different between DES and BMS patients. However, after the discontinuation of clopidogrel (between months 7 and 18), these events occurred in 4.9\% after DES versus 1.3\% after BMS implantation. Target vessel revascularization remained lower after DES, resulting in similar rates of all clinical events for this time period (DES 9.3\%, BMS 7.9\%). Documented late stent thrombosis and related death/target vessel MI were twice as frequent after DES versus BMS (2.6\% vs. 1.3\%). Thrombosis-related events occurred between 15 and 362 days after the discontinuation of clopidogrel, presenting as MI or death in 88\%. CONCLUSIONS: After the discontinuation of clopidogrel, the benefit of DES in reducing target vessel revascularization is maintained but has to be balanced against an increase in late cardiac death or nonfatal MI, possibly related to late stent thrombosis. This article was published in J Am Coll Cardiol and referenced in Cardiovascular Pharmacology: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

  • Donald silverberg
    Is correction of iron deficiency a new addition to the treatment of heart failure?
    PPT Version | PDF Version
  • Ahmed Zeidan
    Effects of intravenous iron in chronic kidney disease and heart failure
    PPT Version | PDF Version
  • Bill Hartzel
    Addressing the market demands of parenterals through innovation and risk mitigation that drives reliable supply
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Alabadan B A
    Production of bio-diesel from used groundnut oil from bosso market, Minna, Niger state, Nigeria
    PPT Version | PDF Version
  • Barbara Klajnert-Maculewicz
    Sugar-modified PPI dendrimers as carriers of anti-leukemia drugs
    PPT Version | PDF Version
  • Ana de Guzmán Báez
    Gypsum to Gypsum (GtoG): The European life project that aims to transform the gypsum waste market
    PPT Version | PDF Version
  • Wenru Wang
    Effects of home-based cardiac rehabilitation programme for patients with acute myocardial infarction: A randomized controlled trail
    PPT Version | PDF Version
  • J S Prasad
    Status of medicinal Rice: How they are being used in Kerala, varieties with specific uses, market potential in the country and exports
    PPT Version | PDF Version
  • Rinat Islamov
    Pharmacokinetics (PK) of anti-tuberculosis drug (FS-1) on healthy volunteers: results from the phase I trial
    PPT Version | PDF Version
  • Almas Okassov
    Chemical modification of anticancer Parasporins for decreasing of their toxicity
    PPT Version | PDF Version
  • Sevgi Gungor
    Micelles as nanosized carriers for skin delivery of drugs
    PPT Version | PDF Version
  • Ru Band Lu
    Anti-Inflammation and neuroprotective drugs benefit the treatment of heroin dependent patients
    PPT Version | PDF Version
  • Anita Nair
    BCS-Based Biowaivers: Which Drugs are Eligible?
    PPT Version | PDF Version
  • Richard A. Kenley
    Equilibrium binding interactions between lotrafilcon a soft contact lenses and the two prostaglandin anti-glaucoma drugs Bimatoprost and Tafluprost
    PPT Version | PDF Version

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords